Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 747 (Tilapertin) for Schizophrenia Negative Symptoms
NCT01568229Phase 2Terminated
- Sponsor
- Amgen
- Start
- May 2012
- Primary completion
- Jun 2013
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 2 trial of tilapertin in schizophrenia, sponsored by Amgen. Started May 2012; status: terminated.
02
Drugs
tilapertin
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT01568229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01568229.